Entorhinal Cortex

Overview

The entorhinal cortex (EC) serves as a critical interface between the neocortex and the hippocampal formation, playing a pivotal role in memory consolidation, spatial navigation, and executive function. In the context of neurodegenerative diseases, particularly Alzheimer’s disease (AD) and Parkinson’s disease (PD), the EC emerges as one of the earliest sites of pathological accumulation, making it a focal point for understanding disease progression and developing early diagnostic biomarkers. This article examines the anatomical features, connectivity patterns, and clinical significance of the entorhinal cortex in neurodegenerative disease pathogenesis. ^{1Witter MP (2007) Intrinsic and extrinsic wiring of CA3: implications for memory. Hippocampus 17:769-7722007 · PMID 18842824Open reference}

--- ^{2Palop JJ, Mucke L (2010) Synaptic depression and aberrant excitatory network activity in Alzheimer's disease. Nat Rev Neurosci 11:101-1082010 · PMID 24677273Open reference}

1. Anatomy and Location

1.1 Anatomical Position

The entorhinal cortex is located in the medial temporal lobe, occupying the anterior portion of the parahippocampal gyrus. It lies adjacent to the hippocampus proper and extends laterally to merge with the perirhinal and parahippocampal cortices. The EC is bounded anteriorly by the amygdala and posteriorly by the parasubiculum. Anatomically, it corresponds to Brodmann areas 28 and 35, with the lateral entorhinal area (LEA) representing area 35 and the medial entorhinal area (MEA) representing area 28 1. ^{3(2013) Diffusion tensor imaging of the hippocampus in MCI. J Int Neuropsychol Soc 19:472-4822013 · PMID 23475748Open reference}

1.2 Layer Structure

The entorhinal cortex exhibits a characteristic six-layer cortical organization that distinguishes it from adjacent perirhinal and parahippocampal regions: ^{4(1982) The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-4171982 · PMID 12446509Open reference}

• Layer I (molecular layer): Contains predominantly dendritic fibers and sparse cell bodies; receives input fromLayer II pyramidal cells.

• Layer II (principal cell layer): Contains the famous “stellate cells” that give rise to the perforant path; these cells express high levels of reelin and are selectively vulnerable in AD 2.

• Layer III (pyramidal cell layer): Contains pyramidal neurons that project to the CA1 subfield and subiculum.

• Layer IV (inner plexiform layer): Receives input from the hippocampus via the temporoammonic path.

• Layer V (polymorphic layer): Contains primarily pyramidal cells that project to subcortical structures.

• Layer VI (multiform layer): Projects to the thalamus and claustrum.

The layer-specific organization of the EC is particularly relevant to neurodegenerative processes, as Layer II stellate cells demonstrate selective vulnerability to tau pathology in early AD 3. ^{5(2011) Amyloid-beta induces excitotoxicity in entorhinal cortex. Neurobiol Aging 32:2200-22092011 · PMID 21459350Open reference}

1.3 Regional Subdivisions

The EC is functionally and cytoarchitectonically divided into two major subdivisions: ^{6(2007) Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55:697-7112007 · PMID 28596309Open reference}

1. Medial Entorhinal Area (MEA): Dominated by grid cells in layer II, receives strong input from visuospatial processing regions, and plays a critical role in spatial memory 4.

2. Lateral Entorhinal Area (LEA): Receives input from olfactory and auditory cortices, more involved in object-related memory and non-spatial information processing.

--- ^{7(2009) CSF biomarkers and incipient Alzheimer disease. JAMA 302:1001-10082009 · PMID 19077058Open reference}

2. Role in Memory and Spatial Navigation

2.1 Grid Cells and Spatial Mapping

The entorhinal cortex houses grid cells, a population of neurons that provide a neural substrate for spatial navigation. Discovered by the Moser group in 2005, grid cells fire in a regular, hexagonal pattern that tessellates the environment, creating an internalized coordinate system 5. Grid cells are predominantly located in Layer II of the medial entorhinal cortex, where they exhibit: ^{8(2009) Automated MRI measures identify MCI and AD. Neuroimage 47:114-1242009 · PMID 20421260Open reference}

• Spatial firing fields: Each grid cell fires when the animal occupies multiple locations arranged in a hexagonal grid pattern.

• Grid scale: Different grid cells exhibit different spacing between firing fields, ranging from 25-50 cm in small laboratory environments.

• Phase: Grid fields are offset relative to environmental landmarks, providing relative position information.

The grid system is thought to provide the metric component of spatial representation, interacting with place cells in the hippocampus to form a complete cognitive map 6. ^{9(2018) Topographic distribution of tau in vivo using flortaucipir PET. J Nucl Med 59:1383-13902018 · PMID 29321058Open reference}

2.2 Place Cells and Hippocampal Interactions

While place cells are primarily located in the hippocampal CA1 and CA3 regions, the entorhinal cortex provides critical input that shapes place cell firing properties. The EC receives processed spatial information from the medial septum (via GABAergic connections) and integrates this with landmark-based information from visual and olfactory cortices. Notably, experimental studies demonstrate that: ^{10(2017) Free-water imaging of the entorhinal cortex in early AD. Neuroimage Clin 15:558-5652017 · PMID 29676929Open reference}

• Disconnection of EC from hippocampus disrupts place cell firing patterns.

• EC lesions produce profound deficits in spatial memory tasks without affecting baseline hippocampal activity.

• Tau pathology in EC correlates with navigational deficits in early AD patients 7.

2.3 Memory Consolidation and Retrieval

Beyond spatial navigation, the EC plays a essential role in episodic memory formation. The EC serves as the “gateway” for information flow between the neocortex and hippocampus, facilitating the encoding, consolidation, and retrieval of memories. The EC is thought to: ^{2Palop JJ, Mucke L (2010) Synaptic depression and aberrant excitatory network activity in Alzheimer's disease. Nat Rev Neurosci 11:101-1082010 · PMID 24677273Open reference}0

1. Bind cortical representations: Integrate sensory information from multiple neocortical areas into coherent episodic memories.

2. Support memory consolidation: During slow-wave sleep, EC-hippocampal interactions enable systems consolidation of hippocampal-dependent memories to neocortical networks.

3. Enable memory retrieval: Provide contextual retrieval cues based on stored memory traces.

--- ^{2Palop JJ, Mucke L (2010) Synaptic depression and aberrant excitatory network activity in Alzheimer's disease. Nat Rev Neurosci 11:101-1082010 · PMID 24677273Open reference}1

3. Early Tau Pathology in Alzheimer’s Disease

3.1 Braak Staging and EC Involvement

The Braak staging system, developed by Heiko and Eva Braak, describes the progression of neurofibrillary tau pathology in AD 8. The entorhinal cortex is affected in the earliest stages of this progression:

Stage	Anatomical Regions Affected	Clinical Significance
I-II	Transentorhinal region, EC (Layers II, III)	Preclinical, subtle memory complaints
III-IV	Hippocampus, amygdala, basal forebrain	Mild cognitive impairment
V-VI	Neocortex, especially association areas	Moderate to severe dementia

Critically, the EC shows neurofibrillary tangle (NFT) accumulation beginning at Braak stages I-II, preceding significant hippocampal involvement 9. This early involvement makes the EC a critical target for understanding preclinical AD.

3.2 Vulnerability of Layer II Stellate Cells

The selective vulnerability of Layer II EC neurons to tau pathology has been extensively documented. These “stellate cells” demonstrate:

• Early tau accumulation: Hyperphosphorylated tau aggregates first in Layer II neurons, which project via the perforant path to the dentate gyrus.

• Receptor expression: High expression of tau-related kinases (GSK-3β, CDK5) and low expression of protective factors.

• Metabolic demands: High metabolic activity and mitochondrial density may predispose these cells to oxidative stress.

• Connectivity consequences: Loss of Layer II neurons disrupts EC-hippocampal communication, contributing to episodic memory deficits 10.

3.3 Transentorhinal Cortex as Entry Point

The transentorhinal cortex (TEC), a transitional zone between the EC and the temporal neocortex, represents the initial site of tau pathology in many cases. The TEC shows neurofibrillary changes in the absence of significant amyloid deposition, suggesting that tau pathology may initiate independently of amyloid-β 11. This finding has implications for understanding disease chronology and therapeutic targeting.

---

4. Connectivity with the Hippocampus: The Perforant Path

4.1 Anatomical Organization

The perforant path constitutes the major white matter tract connecting the entorhinal cortex to the hippocampal formation. This pathway arises primarily from Layer II stellate cells (lateral and medial portions) and Layer III pyramidal cells, projecting to:

• Dentate gyrus (granule cell layer and molecular layer)

• CA3 (stratum lucidum and radiatum)

• CA1 (stratum radiatum and lacunosum-moleculare)

The perforant path is organized into two major components:

1. Medial perforant path: Originates from the MEA, terminates in the outer molecular layer of the dentate gyrus, carries spatial information.

2. Lateral perforant path: Originates from the LEA, terminates in the middle molecular layer, carries object-related information 12.

4.2 Synaptic Organization and Plasticity

The perforant path-dentate gyrus synapse demonstrates long-term potentiation (LTP), a cellular correlate of learning and memory. Key features include:

• NMDA receptor dependence: LTP induction requires activation of NMDA receptors containing GluN2A and GluN2B subunits.

• Metabotropic glutamate receptor involvement: Group I mGluRs modulate LTP expression and maintenance.

• Sex differences: Female rats demonstrate enhanced LTP compared to males, potentially relevant to the higher AD prevalence in women.

In AD, perforant path synaptic integrity is compromised by both tau pathology and amyloid-β toxicity, contributing to memory dysfunction 13.

4.3 Perforant Path in Neurodegeneration

Structural and functional changes in the perforant path are among the earliest biomarkers of AD:

• Diffusion tensor imaging shows reduced fractional anisotropy in the perforant path in MCI and early AD 14.

• Postmortem studies reveal reduced synapse density in the outer molecular layer of the dentate gyrus.

• Animal models demonstrate that experimental tauopathy in EC disrupts perforant path function before hippocampal pathology develops.

---

5. Neurotransmitter Systems

5.1 Cholinergic System

The EC receives significant cholinergic input from the basal forebrain (specifically, the medial septum and diagonal band of Broca). This cholinergic innervation is critical for:

• Attention and memory: Acetylcholine release in EC facilitates encoding of new information.

• Theta rhythm generation: Cholinergic neurons drive hippocampal theta oscillations necessary for spatial navigation.

• Modulation of grid cells: Acetylcholine influences grid cell firing properties and spatial coding precision.

In AD, basal forebrain cholinergic neurons degenerate early, leading to decreased cholinergic tone in the EC and hippocampus. This cholinergic deficit correlates with memory impairment and represents the basis for acetylcholinesterase inhibitor therapy 15.

5.2 Glutamatergic System

The EC expresses high levels of glutamate receptors, particularly:

• NMDA receptors: Critical for synaptic plasticity and memory formation.

• AMPA receptors: Mediate fast excitatory transmission.

• mGluR5: Present on dendritic spines, involved in calcium signaling and LTP.

Excessive glutamate excitotoxicity has been implicated in EC neurodegeneration, particularly in the presence of amyloid-β and tau pathology. The EC shows increased vulnerability to excitotoxic stress due to its high density of calcium-permeable AMPA receptors 16.

5.3 GABAergic System

Local GABAergic interneurons in the EC modulate principal cell activity and network oscillations. Several subtypes have been characterized:

• Parvalbumin-positive cells: Fast-spiking interneurons that control perisomatic inhibition.

• Somatostatin-positive cells: Dendrite-targeting interneurons that modulate integration.

• Cholecystokinin-positive cells: Control dendritic inhibition during specific behavioral states.

GABAergic dysfunction in the EC contributes to network hyperexcitability and seizures, which are increasingly recognized as complications of AD 17.

5.4 Dopaminergic and Noradrenergic Systems

The EC receives sparse dopaminergic input from the ventral tegmental area and noradrenergic input from the locus coeruleus. These modulatory systems influence:

• Memory consolidation: Dopamine facilitates memory stabilization during salient events.

• Arousal and attention: Noradrenergic signaling modulates cortical processing.

• Synaptic plasticity: Both systems modulate LTP induction in the perforant path.

---

6. Clinical Relevance: Biomarkers and Imaging

6.1 Cerebrospinal Fluid Biomarkers

Cerebrospinal fluid (CSF) biomarkers reflect molecular changes in the EC:

• Total tau (t-tau): Elevated in AD, reflects neuronal damage including EC neurodegeneration.

• Phosphorylated tau (p-tau): Specifically elevated in AD, correlates with NFT burden in the EC 18.

• t-tau/p-tau ratio: Emerging biomarker that may distinguish AD from other dementias.

The combination of Amyloid-β42 (reduced) and p-tau181 (elevated) in CSF shows high sensitivity for detecting AD pathology, including early EC involvement.

6.2 Neuroimaging Markers

Structural MRI

Volumetric MRI shows early atrophy of the entorhinal cortex in MCI and preclinical AD:

• EC volume loss precedes hippocampal atrophy by approximately 1-2 years.

• EC thickness measurement provides better discrimination than volume in early stages.

• Baseline EC volume predicts progression from MCI to AD with moderate accuracy 19.

PET Imaging

• Tau PET (e.g., using flortaucipir): Shows elevated binding in the EC in early AD, correlating with memory impairment 20.

• Amyloid PET: EC shows relatively less amyloid than other regions in early stages.

• FDG-PET: Shows hypometabolism in the EC and hippocampus in AD.

Diffusion Imaging

• DTI reveals microstructural changes in the perforant path and EC white matter.

• Free-water imaging shows increased extracellular space in the EC, indicating neurodegeneration 21.

6.3 Clinical Testing

Clinical assessment of EC function includes:

• Episodic memory tests sensitive to EC-hippocampal dysfunction (e.g., word list learning, verbal memory).

• Spatial navigation tasks that specifically probe grid cell and place cell function.

• Olfactory testing: The EC processes olfactory information; odor identification deficits may indicate EC pathology.

---

7. Therapeutic Targeting

7.1 Disease-Modifying Approaches

Anti-Tau Therapies

Given the early involvement of tau pathology in the EC, several tau-targeting strategies are under investigation:

• Active vaccination: Tau vaccines (e.g., AADvac1) aim to generate antibodies against pathological tau species.

• Passive immunotherapy: Anti-tau antibodies (e.g., semorinemab, gosuranemab) target extracellular tau.

• Small molecule inhibitors: Kinase inhibitors (e.g., GSK-3β inhibitors) and aggregation inhibitors.

Early intervention targeting EC tau may prevent downstream hippocampal dysfunction 22.

Anti-Amyloid Therapies

While amyloid-β deposition in the EC is less prominent than in neocortex, amyloid may contribute to EC dysfunction through:

• Synaptic toxicity at perforant path terminals.

• Dysregulation of calcium homeostasis.

• Enhancement of tau pathology propagation.

Monoclonal antibodies targeting Aβ (lecanemab, donanemab) show modest clinical benefit in early AD, potentially through effects on synaptic protection in EC and hippocampus.

7.2 Neuroprotective Strategies

Cholinergic Enhancement

• Acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) provide symptomatic benefit by enhancing cholinergic transmission in EC and hippocampus.

• Muscarinic agonists (e.g., xanomeline) show promise in clinical trials for cognitive enhancement.

Neuroinflammation Modulation

Microglial activation in the EC contributes to neurodegeneration:

• TREM2 variants increase AD risk and alter microglial response to pathology.

• CSF1R antagonists reduce microglial proliferation and neuroinflammation in preclinical models 23.

7.3 Regenerative Approaches

• Stem cell therapy: Animal studies show that transplanted neural progenitor cells can differentiate into EC neurons and improve memory function.

• Brain stimulation: Deep brain stimulation of the EC or fornix shows promise for memory enhancement in AD.

• Network modulation: Non-invasive brain stimulation (tDCS, rTMS) targeting EC-hippocampal circuits may enhance memory.

---

8. Entorhinal Cortex in Parkinson’s Disease

While AD is the primary neurodegenerative condition affecting the EC, Parkinson’s disease and related disorders also involve the EC:

8.1 Lewy Body Pathology

In Parkinson’s disease with dementia (PDD) and dementia with Lewy bodies (DLB), Lewy bodies (composed of α-synuclein) accumulate in the EC:

• EC involvement correlates with cognitive impairment in PD.

• α-Synuclein pathology in EC disrupts grid cell function, contributing to spatial navigation deficits.

• Co-pathology (AD-type tau plus Lewy bodies) is common and produces more severe cognitive decline.

8.2 Non-Motor Symptoms

EC pathology in PD contributes to:

• Olfactory dysfunction: The EC processes olfactory information; early olfactory deficits may reflect EC involvement.

• REM sleep behavior disorder: EC dysfunction may disrupt sleep-wake cycling.

• Depression and apathy: Limbic system involvement including EC contributes to psychiatric symptoms.

8.3 Imaging Findings

• Structural MRI shows EC atrophy in PDD, more severe than in non-demented PD.

• FDG-PET reveals hypometabolism in the EC in PDD.

• Diffusion imaging shows microstructural changes in the EC and perforant path.

---

9. Cross-References and Further Reading

For related topics, see:

• Hippocampus - Primary target of EC output, critical for memory consolidation.

• Alzheimer’s Disease - Primary neurodegenerative disease affecting EC.

• Parkinson’s Disease - Second most common neurodegenerative cause of dementia.

• Tauopathy - Group of neurodegenerative diseases characterized by tau pathology.

• Perforant Path - Major connection between EC and hippocampus.

• Grid Cells - Spatial navigation neurons located in medial EC.

• Place Cells - Spatial memory neurons in hippocampus receiving EC input.

• Braak Staging - Neuropathological staging system for AD tau pathology.

• Mild Cognitive Impairment - Clinical stage often characterized by EC atrophy.

• Neurofibrillary Tangle - Intraneuronal tau aggregates in AD.

• Basal Forebrain Cholinergic System - Key modulator of EC function.

• Perirhinal Cortex - Adjacent cortical region involved in object memory.

• Parahippocampal Cortex - Cortical region containing the EC.

---

10. Conclusion

The entorhinal cortex represents a critical hub in the neural circuitry underlying memory, spatial navigation, and executive function. Its early and selective involvement in Alzheimer’s disease, characterized by tau pathology beginning in Layer II, makes it a key structure for understanding disease progression and developing early diagnostic biomarkers. The EC’s unique position as the gateway between the neocortex and hippocampus, combined with its role in grid cell-based spatial mapping, provides a mechanistic link between molecular pathology and clinical symptoms of neurodegeneration. Future therapeutic strategies targeting the EC—whether through anti-tau immunotherapies, neuroprotective agents, or network modulation—hold promise for intervening in the earliest stages of neurodegenerative diseases before widespread hippocampal and cortical damage occurs.

---

See Also

• Alzheimer’s Disease

• Parkinson’s Disease

External Links

• PubMed

• KEGG Pathways

Brain Atlas Resources

• [Allen Human Brain Atlas**: Entorhinal Cortex expression searchallen-human-brain-atlas)

• [Allen Mouse Brain Atlas**: Entorhinal Cortex searchbrain-atlas)

• [Allen Cell Type Atlas**: Transcriptomic cell type referenceatlas)

• [BrainSpan Developmental Transcriptome**: Entorhinal Cortex developmental expressionbrainspan)